Neuroprotection through G-CSF: recent advances and future viewpoints

Simple item page
dc.contributor.authorRahi, Vikrant
dc.contributor.authorJamwal, Sumit
dc.contributor.authorKumar, Puneet
dc.date.accessioned2024-01-21T10:54:57Z
dc.date.accessioned2024-08-14T07:44:20Z
dc.date.available2024-01-21T10:54:57Z
dc.date.available2024-08-14T07:44:20Z
dc.date.issued2021-01-02T00:00:00
dc.description.abstractGranulocyte-colony stimulating factor (G-CSF), a member of the cytokine family of hematopoietic growth factors, is 19.6�kDa glycoprotein which is responsible for the proliferation, maturation, differentiation, and survival of neutrophilic granulocyte lineage. Apart from its proven clinical application to treat chemotherapy-associated neutropenia, recent pre-clinical studies have highlighted the neuroprotective roles of G-CSF i.e., mobilization of haemopoietic stem cells, anti-apoptotic, neuronal differentiation, angiogenesis and anti-inflammatory in animal models of neurological disorders. G-CSF is expressed by numerous cell types including neuronal, immune and endothelial cells. G-CSF is released in autocrine manner and binds to its receptor G-CSF-R which further activates numerous signaling transduction pathways including PI3K/AKT, JAK/STAT and MAP kinase, and thereby promote neuronal survival, proliferation, differentiation, mobilization of hematopoietic stem and progenitor cells. The expression of G-CSF receptors (G-CSF-R) in the different brain regions and their upregulation in response to neuronal insult indicates the autocrine protective signaling mechanism of G-CSF by inhibition of apoptosis, inflammation, and stimulation of neurogenesis. These observed neuroprotective effects of G-CSF makes it an attractive target to mitigate neurodegeneration associated with neurological disorders. The objective of the review is to highlight and summarize recent updates on G-CSF as a therapeutically versatile neuroprotective agent along with mechanisms of action as well as possible clinical applications in neurodegenerative disorders including AD, PD and HD. � 2021, Maj Institute of Pharmacology Polish Academy of Sciences.en_US
dc.identifier.doi10.1007/s43440-020-00201-3
dc.identifier.issn22995684
dc.identifier.urihttp://10.2.3.109/handle/32116/4285
dc.identifier.urlhttps://link.springer.com/10.1007/s43440-020-00201-3
dc.language.isoen_USen_US
dc.publisherSpringer Science and Business Media Deutschland GmbHen_US
dc.subjectAlzheimer�s diseaseen_US
dc.subjectGranulocyte-colony stimulating factoren_US
dc.subjectGranulocyte-colony stimulating factor-receptorsen_US
dc.subjectHuntington�s diseaseen_US
dc.subjectNeuroprotectionen_US
dc.subjectParkinson�s diseaseen_US
dc.titleNeuroprotection through G-CSF: recent advances and future viewpointsen_US
dc.title.journalPharmacological Reportsen_US
dc.typeReviewen_US
dc.type.accesstypeClosed Accessen_US

Files

Collections

Pharmacology - Research Publications